Personal Capital Advisors’s Arcus Biosciences RCUS Stock Holding History

Personal Capital Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,395	Closed	-$246K	–	502
2022 Q3	$246K	Hold	9,395	–	–	﹤0.01%	403
2022 Q2	$238K	Hold	9,395	–	–	﹤0.01%	396
2022 Q1	$297K	Hold	9,395	–	–	﹤0.01%	394
2021 Q4	$380K	Hold	9,395	–	–	﹤0.01%	384
2021 Q3	$328K	Hold	9,395	–	–	﹤0.01%	385
2021 Q2	$258K	Hold	9,395	–	–	﹤0.01%	421
2021 Q1	$264K	Hold	9,395	–	–	﹤0.01%	416
2020 Q4	$244K	Buy	+9,395	New	+$227K	﹤0.01%	417
2020 Q3	–	Sell	-9,395	Closed	-$232K	–	422
2020 Q2	$232K	Buy	+9,395	New	+$254K	﹤0.01%	329

Other funds holding RCUS

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return